Back-to-Back Funding Rounds in Two Months: What’s Driving This Vision Health Innovator?
MetaVision
Provider of Vision Health Management Services for Children and Adolescents
【Viewpoint · Ophthalmology Industry Navigation】
Major Events Monthly Report | Editor's Recommended Article
Winning Atlas· Volume Increase in Centralized Procurement | Ophthalmic Optometry Column
Recently,Shanghai MetaVision Health Technology Co., Ltd.(Abbreviation：“MetaVision”）Announcement CompletedTens of Millions of Yuan in New Round of Financing, just two months after the tens of millions of financing in June this year. This round of financing was led byHuaxi Jinzhi Specialized and Innovative FundLed by, existing shareholdersInnovation WorkshopContinued investment, with Kaiming Capital serving as the exclusive financial advisor. The company stated,The funds will be used forClinical registration, sales expansion, brand building, and R&D investment。
# Core Competitiveness of the Company
MetaVision's advantages stem from its unique technical approach and precise grasp of market demands.
At the technical level, whose core technology——Optical Ocular-Brain Neuromodulation, by precisely adjusting the impact of optical stimulation on the retina, combined with the feedback mechanism of the nervous system,Achieve control over axial length growth and refractive error.Compared with traditional myopia prevention and control technologies, this method has high adaptability and can be adjusted according to the user's specific vision condition and usage habits.
At the hardware level, MetaVision introducedBionic Optical Module, mimicking the distribution and intensity of natural light to enhance myopia intervention effects;
At the algorithm level, through an AI recognition-based intelligent regulation mechanism, precisely outputs according to each teenager's personalized needs.
InClinical ValidationAspectThrough multi-center joint research by authoritative institutions such as Beijing Tongren Hospital and Sichuan Huaxi Hospital, the data shows that their related products areAxial Length Growth ControlAndDelayed Refractive Development——In a real-world study of nearly 200 cases over six months, significant advantages were demonstrated in all aspects.The average axial growth in the MetaVision trial group was only 0.038mm, significantly lower than the 0.125mm in the control group, with individual cases showing refractive improvement.。
At the market level, MetaVision has gradually built a full-chain product system from hardware, algorithms to services. Through cooperation with professional optometry institutions, the company has established sales networks in multiple regions and accumulated a large amount of user data. This data not only helps optimize existing products but also provides an important basis for personalized customization of future products. In addition, MetaVision also plans toExpand Product Application Scenarios, deeply integrating myopia prevention and control technology with daily learning, entertainment, and other activities to further enhance user treatment adherence and product penetration.
Overall, the core competitiveness of MetaVision lies inTechnological Innovation and Market AdaptabilityThe combination of. Through continuous innovation in product functionality and meticulous market cultivation, MetaVision has gradually built up aTechnology-Driven, Data-Supported, Service-OrientedThe growth path.
# Business Model Innovation
MetaVisionBusiness ModelInnovation is reflected in its"Dual Construction of 'Hardware' and 'Service'". Unlike traditional optometry enterprises that rely on single-product sales, MetaVision is advancing with "AI + Data + Service".The integration model, through intelligent feedback and personalized regulation of technology,Achieve Continuous Management of Myopia Prevention and Control. Through the accumulation of the big data platform, the company provides users with not only hardware products but alsoLong-term health management and data support.
Through continuously refined intelligent control algorithms, MetaVision's products can monitor users' eye conditions in real time and adjust treatment plans based on data feedback. This new development by the company...Business ModelBuilt aFull Life Cycle Vision Health Management System, which not only helps to enhance user stickiness but also lays the foundation for long-term revenue growth in the future.
Currently, MetaVision has preliminarily verified the effectiveness of this model in multiple regions, and will further deepen the strategy of "serious medical-driven consumer medical" in the future, gradually promoting the transformation to the "prescription-based treatment" model. Through cooperation with hospitals, optometry centers, and educational institutions, MetaVision plans to comprehensively expand its products and services to schools, families, medical institutions, and more.Create a myopia prevention and control ecosystem with participation from the whole society。
# Industry Leadership and Transformation
In 2025, MetaVisionEye Hospital of Wenzhou Medical UniversityReleased"Technical Specifications for Remote Image Electronic Display Terminals" and "Visual Health Technical Requirements for Display Products - Remote Image Electronic Display Terminals"The introduction of two group standards marks the company's gradual transformation into a rule-maker in the industry based on technological innovation, enhancing MetaVision's influence in the optometry field.
Currently, MetaVision's products have entered a large number of professional optometry institutions, and the real-world myopia prevention and control effects for users are showing significant results.Improve. The company also plans to expand into more educational and entertainment scenarios, promoting the integration of myopia prevention and control technology into teenagers' daily lives. This self-However, it is integrated intoBehavior-Neuro Integration TherapyMode, which is not only expected to significantly improve user compliance, but also break the limitations of traditional treatment methods and expand market boundaries.
MetaVision, established in 2017, pioneered AI Optical Neuro-Modulation technology, integrating artificial intelligence, optical engineering, neuroscience, and clinical optometry. Focusing on key dimensions such as dynamic defocus, photobiology, myopic defocus, and contrast, it develops digital modulation tools to drive the innovation of far-field imaging technology and a comprehensive suite of myopia management digital solutions.
Its products include self-developed and produced distance-based products such as the Vision Training Device D1, Vision Training Device MAX 2.0, and Distance Screen PLUS 2.0, which are equipped with the distance-based defocus digital technology system developed by MetaVision. Using digital display devices as a medium, the system achieves digitalization and personalization of optical defocus, LCA (longitudinal chromatic aberration), contrast, and more through unique optical hardware and software technologies to provide targeted regulation of visual pathways.
GOC2025
Ophthalmology Solutions Case
Research on Ophthalmic Instruments Industry
